Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis

Authors: Saghar Rahnama, Zahra Moazezi Tehrankhah, Fatemeh Mohajerani, Faezeh Shah Mohammadi, Zahra Yousefi Yeganeh, Farhood Najafi, Sadegh Babashah, Majid Sadeghizadeh

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Login to get access

Abstract

Background

Hepatocellular Carcinoma (HCC) is a prevalent form of liver cancer that causes significant mortality in numerous individuals worldwide. This study compared the effects of milk thistle (MT) and nano-milk thistle (N-MT) on the expression of the genes that participate in apoptosis and cell cycle pathways in Huh-7 and HepG2 cells.

Methods

IC50 values of MT and N-MT were determined using the MTT assay. Huh-7 and HepG2 cell lines (containing mutant and wild-type TP53 gene, respectively) were incubated with MT and N-MT for 24h and 48h and the impact of MT and N-MT on the proliferation of these cell lines was evaluated through a comparative analysis. Cell cycle and apoptosis were assessed by flow cytometry after 24h and 48h treatment in the cell lines mentioned. Real-time PCR was used to analyze miR-155-3p, PHLDA1, SOCS2, TP53, P21, BAX, and BCL-2 expression in the cell lines that were being treated.

Results

N-MT reduces cancer cell growth in a time and concentration-dependent manner, which is more toxic compared to MT. Huh-7 was observed to have IC50 values of 2.35 and 1.7 μg/ml at 24h and 48h, and HepG2 was observed to have IC50 values of 3.4 and 2.6 μg/ml at 24 and 48h, respectively. N-MT arrested Huh-7 and HepG2 cells in the Sub-G1 phase and induced apoptosis. N-MT led to a marked reduction in the expression of miR-155-3p and BCL-2 after 24h and 48h treatments. Conversely, PHLDA1, SOCS2, BAX, and P21 were upregulated in the treated cells compared to untreated cells, which suggests that milk thistle has the potential to regulate these genes. N-MT reduced the expression of TP53 in Huh-7 cells after mentioned time points, while there was a significant increase in the expression of the TP53 gene in HepG2 cells. No gene expression changes were observed in MT-treated cells after 24h and 48h.

Conclusion

N-MT can regulate cancer cell death by arresting cell cycle and inducing apoptosis. This occurs through the alteration of apoptotic genes expression. A reduction in the expression of miR-155-3p and increase in the expression of SOCS2 and PHLDA1 after N-MT treatment showed the correlation between miR-155-3p and PHLDA1/SOCS2 found in bioinformatics analysis. While N-MT increased TP53 expression in HepG2, reduced it in Huh-7. The findings indicate that N-MT can function intelligently in cancer cells and can be a helpful complement to cancer treatment.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–30.PubMedCrossRef Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–30.PubMedCrossRef
4.
go back to reference Llovet J, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nature reviews Disease primers. 2016; 2: 16018. Epub 2016/05/10. PubMed PMID: 27158749. https://doi.org/10.1038/nrdp; 2016. Llovet J, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nature reviews Disease primers. 2016; 2: 16018. Epub 2016/05/10. PubMed PMID: 27158749. https://​doi.​org/​10.​1038/​nrdp; 2016.
5.
go back to reference Takke A, Shende P. Nanotherapeutic silibinin: an insight of phytomedicine in healthcare reformation. Nanomedicine: Nanotechnology, Biology and Medicine. 2019;21:102057.PubMedCrossRef Takke A, Shende P. Nanotherapeutic silibinin: an insight of phytomedicine in healthcare reformation. Nanomedicine: Nanotechnology, Biology and Medicine. 2019;21:102057.PubMedCrossRef
6.
go back to reference Gioti K, Papachristodoulou A, Benaki D, Havaki S, Beloukas A, Vontzalidou A, et al. Silymarin enriched extract (Silybum marianum) additive effect on doxorubicin-mediated cytotoxicity in PC-3 prostate cancer cells. Planta Med. 2019;85(11/12):997–1007.PubMedCrossRef Gioti K, Papachristodoulou A, Benaki D, Havaki S, Beloukas A, Vontzalidou A, et al. Silymarin enriched extract (Silybum marianum) additive effect on doxorubicin-mediated cytotoxicity in PC-3 prostate cancer cells. Planta Med. 2019;85(11/12):997–1007.PubMedCrossRef
7.
go back to reference Koltai T, Fliegel L. Role of silymarin in cancer treatment: facts, hypotheses, and questions. J Evid-Based Integrat Medicine. 2022;27:2515690X211068826. Koltai T, Fliegel L. Role of silymarin in cancer treatment: facts, hypotheses, and questions. J Evid-Based Integrat Medicine. 2022;27:2515690X211068826.
8.
go back to reference Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018;32(11):2202–13.PubMedCrossRef Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018;32(11):2202–13.PubMedCrossRef
9.
go back to reference Agarwal C, Wadhwa R, Deep G, Biedermann D, Gažák R, Křen V, et al. Anti-cancer efficacy of silybin derivatives-a structure-activity relationship. PLoS ONE. 2013;8(3):e60074.PubMedPubMedCentralCrossRef Agarwal C, Wadhwa R, Deep G, Biedermann D, Gažák R, Křen V, et al. Anti-cancer efficacy of silybin derivatives-a structure-activity relationship. PLoS ONE. 2013;8(3):e60074.PubMedPubMedCentralCrossRef
10.
go back to reference Khazaei R, Seidavi A, Bouyeh M. A review on the mechanisms of the effect of silymarin in milk thistle (Silybum marianum) on some laboratory animals. Veterinary Medicine and Science. 2022;8(1):289–301.PubMedCrossRef Khazaei R, Seidavi A, Bouyeh M. A review on the mechanisms of the effect of silymarin in milk thistle (Silybum marianum) on some laboratory animals. Veterinary Medicine and Science. 2022;8(1):289–301.PubMedCrossRef
11.
go back to reference Yassin NY, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother. 2022;145:112409.PubMedCrossRef Yassin NY, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother. 2022;145:112409.PubMedCrossRef
12.
go back to reference Chota A, George BP, Abrahamse H. Interactions of multidomain pro-apoptotic and anti-apoptotic proteins in cancer cell death. Oncotarget. 2021;12(16):1615.PubMedPubMedCentralCrossRef Chota A, George BP, Abrahamse H. Interactions of multidomain pro-apoptotic and anti-apoptotic proteins in cancer cell death. Oncotarget. 2021;12(16):1615.PubMedPubMedCentralCrossRef
14.
go back to reference Montazeri M, Pilehvar-Soltanahmadi Y, Mohaghegh M, Panahi A, Khodi S, Zarghami N, et al. Antiproliferative and apoptotic effect of dendrosomal curcumin nanoformulation in P53 mutant and wide-type cancer cell lines. Anti-Cancer Agents Medicinal Chemist (formerly current medicinal chemistry-anti-cancer agents). 2017;17(5):662–73. Montazeri M, Pilehvar-Soltanahmadi Y, Mohaghegh M, Panahi A, Khodi S, Zarghami N, et al. Antiproliferative and apoptotic effect of dendrosomal curcumin nanoformulation in P53 mutant and wide-type cancer cell lines. Anti-Cancer Agents Medicinal Chemist (formerly current medicinal chemistry-anti-cancer agents). 2017;17(5):662–73.
15.
go back to reference Neef Rd, Kuske MA, Pröls E, Johnson JP. Identification of the human PHLDA1/TDAG51 gene down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Research. 2002;62(20):5920–9 Neef Rd, Kuske MA, Pröls E, Johnson JP. Identification of the human PHLDA1/TDAG51 gene down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Research. 2002;62(20):5920–9
17.
go back to reference Xu B, Lv W, Li X, Zhang L, Lin J. Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis. J Cell Biochem. 2019;120(7):11616–23.PubMedCrossRef Xu B, Lv W, Li X, Zhang L, Lin J. Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis. J Cell Biochem. 2019;120(7):11616–23.PubMedCrossRef
18.
go back to reference Liu J, Liu Z, Li W, Zhang S. SOCS2 is a potential prognostic marker that suppresses the viability of hepatocellular carcinoma cells. Oncol Lett. 2021;21(5):1–10.CrossRef Liu J, Liu Z, Li W, Zhang S. SOCS2 is a potential prognostic marker that suppresses the viability of hepatocellular carcinoma cells. Oncol Lett. 2021;21(5):1–10.CrossRef
19.
go back to reference Ebrahimi M, Babaei E, Neri F, Feizi MAH. Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines. Int J Pharm. 2021;601: 120592.PubMedCrossRef Ebrahimi M, Babaei E, Neri F, Feizi MAH. Anti-proliferative and apoptotic effect of gemini curcumin in p53-wild type and p53-mutant colorectal cancer cell lines. Int J Pharm. 2021;601: 120592.PubMedCrossRef
22.
go back to reference Hajjari M, Rahnama S. HOTAIR long non-coding RNA: characterizing the locus features by the in silico approaches. Genomics & Informatics. 2017;15(4):170.CrossRef Hajjari M, Rahnama S. HOTAIR long non-coding RNA: characterizing the locus features by the in silico approaches. Genomics & Informatics. 2017;15(4):170.CrossRef
24.
go back to reference Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18.PubMedCrossRef Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18.PubMedCrossRef
26.
go back to reference Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3(10):1113–21. Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3(10):1113–21.
27.
go back to reference Lu T, Rothenberg M. Allergy Clin. Immunol. 2018;141(4):1202–7. Lu T, Rothenberg M. Allergy Clin. Immunol. 2018;141(4):1202–7.
28.
go back to reference Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.PubMedCrossRef Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.PubMedCrossRef
29.
go back to reference Su K, Wang N, Shao Q, Liu H, Zhao B, Ma S. The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression. Biomed Pharmacother. 2021;137: 111389.PubMedCrossRef Su K, Wang N, Shao Q, Liu H, Zhao B, Ma S. The role of a ceRNA regulatory network based on lncRNA MALAT1 site in cancer progression. Biomed Pharmacother. 2021;137: 111389.PubMedCrossRef
30.
go back to reference Rahnama S, Bakhshinejad B, Farzam F, Bitaraf A, Ghazimoradi MH, Babashah S. Identification of dysregulated competing endogenous RNA networks in glioblastoma: A way toward improved therapeutic opportunities. Life Sci. 2021;277: 119488.PubMedCrossRef Rahnama S, Bakhshinejad B, Farzam F, Bitaraf A, Ghazimoradi MH, Babashah S. Identification of dysregulated competing endogenous RNA networks in glioblastoma: A way toward improved therapeutic opportunities. Life Sci. 2021;277: 119488.PubMedCrossRef
31.
go back to reference Tang B, Lei B, Qi G, Liang X, Tang F, Yuan S, et al. MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. J Exp Clin Cancer Res. 2016;35:1–12.CrossRef Tang B, Lei B, Qi G, Liang X, Tang F, Yuan S, et al. MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression. J Exp Clin Cancer Res. 2016;35:1–12.CrossRef
32.
go back to reference Farsani SSM, Sadeghizadeh M, Gholampour MA, Safari Z, Najafi F. Nanocurcumin as a novel stimulator of megakaryopoiesis that ameliorates chemotherapy-induced thrombocytopenia in mice. Life Sci. 2020;256:117840.CrossRef Farsani SSM, Sadeghizadeh M, Gholampour MA, Safari Z, Najafi F. Nanocurcumin as a novel stimulator of megakaryopoiesis that ameliorates chemotherapy-induced thrombocytopenia in mice. Life Sci. 2020;256:117840.CrossRef
33.
go back to reference Sadeghizadeh M, Asadollahi E, Jahangiri B, Yadollahzadeh M, Mohajeri M, Afsharpad M, et al. Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: A randomized, double-blinded, placebo-controlled trial. Phytother Res. 2023;37(8):3631–44.PubMedCrossRef Sadeghizadeh M, Asadollahi E, Jahangiri B, Yadollahzadeh M, Mohajeri M, Afsharpad M, et al. Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: A randomized, double-blinded, placebo-controlled trial. Phytother Res. 2023;37(8):3631–44.PubMedCrossRef
34.
go back to reference Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer. 2022;3(4):386–401.PubMedPubMedCentralCrossRef Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer. 2022;3(4):386–401.PubMedPubMedCentralCrossRef
35.
go back to reference McGlynn K, Petrick J, El-Serag H. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13.PubMedCrossRef McGlynn K, Petrick J, El-Serag H. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13.PubMedCrossRef
36.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
37.
go back to reference Zou G, Park J-I. Wnt signaling in liver regeneration, disease, and cancer. Clin Mol Hepatol. 2023;29(1):33.PubMedCrossRef Zou G, Park J-I. Wnt signaling in liver regeneration, disease, and cancer. Clin Mol Hepatol. 2023;29(1):33.PubMedCrossRef
38.
go back to reference Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.PubMedPubMedCentralCrossRef Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.PubMedPubMedCentralCrossRef
39.
go back to reference Gong D, Li S, Yu Z, Wang K, Qiao X, Wu C. Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population. BMC Med Genomics. 2022;15(1):248.PubMedPubMedCentralCrossRef Gong D, Li S, Yu Z, Wang K, Qiao X, Wu C. Contribution of PNPLA3 gene polymorphisms to hepatocellular carcinoma susceptibility in the Chinese Han population. BMC Med Genomics. 2022;15(1):248.PubMedPubMedCentralCrossRef
40.
go back to reference Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem. 2021;224: 113690.PubMedCrossRef Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem. 2021;224: 113690.PubMedCrossRef
41.
go back to reference Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020;1873(1):188314. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2020;1873(1):188314.
43.
go back to reference Zhao C-q, Zhou Y, Ping J, Xu L-m. Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities. Journal of integrative medicine. 2014;12(5):401–8. Zhao C-q, Zhou Y, Ping J, Xu L-m. Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities. Journal of integrative medicine. 2014;12(5):401–8.
44.
go back to reference Emadi SA, Ghasemzadeh Rahbardar M, Mehri S, Hosseinzadeh H. A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents. Iran J Basic Med Sci. 2022;25(10):1166–76. Emadi SA, Ghasemzadeh Rahbardar M, Mehri S, Hosseinzadeh H. A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents. Iran J Basic Med Sci. 2022;25(10):1166–76.
45.
go back to reference Chen C-H, Huang T-S, Wong C-H, Hong C-L, Tsai Y-H, Liang C-C, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol. 2009;47(3):638–44.PubMedCrossRef Chen C-H, Huang T-S, Wong C-H, Hong C-L, Tsai Y-H, Liang C-C, et al. Synergistic anti-cancer effect of baicalein and silymarin on human hepatoma HepG2 Cells. Food Chem Toxicol. 2009;47(3):638–44.PubMedCrossRef
46.
go back to reference Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu Z-X, Chen Z-S, et al. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges. Front Oncol. 2022;12:1041.CrossRef Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu Z-X, Chen Z-S, et al. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges. Front Oncol. 2022;12:1041.CrossRef
47.
go back to reference Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)—Chemistry, bioavailability, and metabolism. Molecules. 2017;22(11):1942. Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)—Chemistry, bioavailability, and metabolism. Molecules. 2017;22(11):1942.
48.
49.
go back to reference Tyagi A, Singh RP, Agarwal C, Agarwal R. Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis. 2006;27(11):2269–80.PubMedCrossRef Tyagi A, Singh RP, Agarwal C, Agarwal R. Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4 cells: evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis. 2006;27(11):2269–80.PubMedCrossRef
50.
go back to reference Hosseinabadi T, Lorigooini Z, Tabarzad M, Salehi B, Rodrigues CF, Martins N, et al. Silymarin antiproliferative and apoptotic effects: insights into its clinical impact in various types of cancer. Phytother Res. 2019;33(11):2849–61.PubMedCrossRef Hosseinabadi T, Lorigooini Z, Tabarzad M, Salehi B, Rodrigues CF, Martins N, et al. Silymarin antiproliferative and apoptotic effects: insights into its clinical impact in various types of cancer. Phytother Res. 2019;33(11):2849–61.PubMedCrossRef
51.
go back to reference Vaskivuo TE, Stenbäck F, Tapanainen JS. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-α, and NF-κB in human endometrial hyperplasia and carcinoma. Cancer. 2002;95(7):1463–71.PubMedCrossRef Vaskivuo TE, Stenbäck F, Tapanainen JS. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-α, and NF-κB in human endometrial hyperplasia and carcinoma. Cancer. 2002;95(7):1463–71.PubMedCrossRef
54.
go back to reference Zadeh MM, Motamed N, Ranji N, Majidi M, Falahi F. Silibinin-induced apoptosis and downregulation of microRNA-21 and microRNA-155 in MCF-7 human breast cancer cells. J Breast Cancer. 2016;19(1):45–52. Zadeh MM, Motamed N, Ranji N, Majidi M, Falahi F. Silibinin-induced apoptosis and downregulation of microRNA-21 and microRNA-155 in MCF-7 human breast cancer cells. J Breast Cancer. 2016;19(1):45–52.
Metadata
Title
Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis
Authors
Saghar Rahnama
Zahra Moazezi Tehrankhah
Fatemeh Mohajerani
Faezeh Shah Mohammadi
Zahra Yousefi Yeganeh
Farhood Najafi
Sadegh Babashah
Majid Sadeghizadeh
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-023-04168-5

Other articles of this Issue 1/2023

BMC Complementary Medicine and Therapies 1/2023 Go to the issue